Five years ago, the FDA approved the first liquid biopsy test for use in patients with cancer, providing cancer teams and patients a less invasive and more efficient way to detect disease. But liquid biopsies aren’t cheap, and reimbursement for them can be unpredictable and confusing.

On this episode of CANCER BUZZ, learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.

Guests:

• J. Nicholas Bodor, MD, PhD, MPH, Assistant Professor, Department of Hematology/Oncology, Fox Chase Cancer Center
• Kathryn A. Phillips, PhD, Professor of Health Economics and Health Services Research; Director, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco

Related Content:

• BiomarkerLIVE
• On-Demand Webinar: Biomarker Testing Cost & Coverage
• Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies from 2015 to 2019, JNCCN
• Reimbursement Challenges and Solutions with Molecular Biomarker Testing, JONS
• Biomarker Testing for Cancer Patients: Barriers and Solutions Part 5, Lablogatory

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.